Hugh Sinclair Lecture: The regulation and remodelling of HDL by plasma factors

Atherosclerosis Supplements

Volumn 3, Issue 4, 2002, Pages 39-47

  Barter, P J ^a,b  

^a HANSON INSTITUTE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

CETP; HDL remodelling; HDL subpopulations; High density lipoproteins

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; ANTISENSE OLIGODEOXYNUCLEOTIDE; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; CHOLESTEROL; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; PLASMA PROTEIN;

ATHEROSCLEROSIS; CELL MEMBRANE; CHOLESTEROL TRANSPORT; CONFERENCE PAPER; DISSOCIATION; DRUG MECHANISM; DRUG TARGETING; DYNAMICS; ESTERIFICATION; EXTRACELLULAR SPACE; HUMAN; HYDROLYSIS; LIPID COMPOSITION; LIPOPROTEIN METABOLISM; NONHUMAN; PLASMA FACTOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; REGULATORY MECHANISM; STRUCTURE ANALYSIS; TRANSPORT KINETICS; ARTERIOSCLEROSIS; DRUG EFFECT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; ULTRASTRUCTURE;

APOLIPOPROTEIN A-I; ARTERIOSCLEROSIS; BLOOD PROTEINS; HUMANS; LIPOPROTEINS, HDL;

EID: 0038352226     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(02)00041-7     Document Type: Conference Paper

References (55)

1. Rye K.-A., Clay M.A., Barter P.J. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis. 145:1999;227-238.
2. Blanche P.J., Gong E.L., Forte T.M., Nichols A.V. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim. Biophys. Acta. 665:1981;408-419.
3. Cheung M.C., Albers J.J. Characterization of lipoprotein particles by immunoaffinity chromatography. J. Biol. Chem. 259:1984;12201-12209.
4. Bekaert E.D., Alaupovic P., Knight-Gibson C., Norum R.A., Laux M.J., Ayrault-Jarrier M. Isolation and partial characterization of lipoprotein A-II (LP-A-II) particles of human plasma. Biochim. Biophys. Acta. 1126:1992;105-113.
5. Cheung M.C., Albers J.J. Distribution of high density lipoprotein particles with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. J. Lipid Res. 23:1982;747-753.
6. Asztalos B.F., Sloop C.H., Wong L., Roheim P.S. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim. Biophys. Acta. 1169:1993;291-300.
7. Huang Y., von Eckardstein A., Wu S., Assmann G. Effects of the apolipoprotein E polymorphism on uptake and transfer of cell-derived cholesterol in plasma. J. Clin. Invest. 96:1995;2693-2701.
8. Kunitake S.T., La Sala K.J., Kane J.P. Apolipoprotein A-I-containing lipoproteins with pre-beta electrophoretic mobility. J. Lipid Res. 26:1985;549-555.
9. Sparks D.L., Lund-Katz S., Phillips M.C. The charge and structural stability of apolipoprotein A-I in discoidal and spherical recombinant high density lipoprotein particles. J. Biol. Chem. 267:1992;25839-25847.
10. Fielding C.J., Fielding P.E. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36:1995;211-228.
11. Lawn R.M., Wade D.P., Garvin M.R., Wang X., Schwartz K., Porter J.G., et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J. Clin. Invest. 104:1999;R25-R31.
12. Bodzioch M., Orso E., Klucken J., Langmann T., Bottcher A., Diederich W., et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22:1999;347-351.
13. Brooks-Wilson A., Marcil M., Clee S.M., Zhang L.H., Roomp K., van Dam M., et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22:1999;336-345.
14. Orso E., Broccardo C., Kaminski W.E., Bottcher A., Liebisch G., Drobnik W., et al. Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient mice. Nat. Genet. 24:2000;192-196.
15. Rust S., Rosier M., Funke H., Real J., Amoura Z., Piette J.C., et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 22:1999;352-355.
16. Glomset J.A. The plasma lecithin:cholesterol acyltransferase reaction. J. Lipid Res. 9:1968;155-167.
17. Jonas A. Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins. Biochim. Biophys. Acta. 1084:1991;205-220.
18. Tall A.R. Plasma cholesteryl ester transfer protein. J. Lipid Res. 34:1993;1255-1274.
19. Barter P.J., Hopkins C.J., Calvert G.D. Transfers and exchanges of esterified cholesterol between plasma lipoproteins. Biochem. J. 208:1982;1-7.
20. Hime N.J., Barter P.J., Rye K.-A. The influence of apolipoprotein on the hepatic lipase-mediated hydrolysis of high density lipoprotein phospholipid and triacylglycerol. J. Biol. Chem. 273:1998;27191-27199.
21. Qin S., Kawano K., Bruce C., Lin M., Bisgaier C., Tall A.R., et al. Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins. J. Lipid Res. 41:2000;269-276.
22. Liang H.-Q., Rye K.-A., Barter P.J. Cycling of apolipoprotein A-I between lipid-associated and lipid-free pools. Biochim. Biophys. Acta. 1257:1995;31-37.
23. Castro G.R., Fielding C.J. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. Biochemistry. 27:1998;25-29.
24. Johnson W.J., Mahlberg F.H., Rothblat G.H., Phillips M.C. Cholesterol transport between cells and high-density lipoproteins. Biochim. Biophys. Acta. 1085:1991;273-298.
25. Liang H.-Q., Rye K.-A., Barter P.J. Remodelling of reconstituted high density lipoproteins by lecithin: cholesterol acyltransferase. J. Lipid Res. 37:1996;1962-1970.
26. Korhonen A., Jauhiainen M., Ehnholm C., Kovanen P.T., Ala-Korpela M. Remodeling of HDL by phospholipid transfer protein: demonstration of particle fusion by 1H NMR spectroscopy. Biochem. Biophys. Res. Commun. 249:1998;910-916.
27. Rye K.A., Jauhiainen M., Barter P.J., Ehnholm C. Triglyceride-enrichment of high density lipoproteins enhances their remodelling by phospholipid transfer protein. J. Lipid Res. 39:1998;613-622.
28. Rye K.-A., Hime H.J., Barter P.J. The influence of cholesteryl ester transfer protein on the composition, size and structure of spherical, reconstituted high density lipoproteins. J. Biol. Chem. 270:1995;189-196.
29. Clay M.A., Newnham H.H., Forte T.M., Barter P.J. Cholesteryl ester transfer protein and hepatic lipase activity promote shedding of apo A-I from HDL and subsequent formation of discoidal HDL. Biochim. Biophys. Acta. 1124:1992;52-58.
30. Clay M.A., Barter P.J. Formation of new HDL particles from lipid-free apolipoprotein A-I. J. Lipid Res. 7:1996;1722-1732.
31. Horowitz B.S., Goldberg I.J., Merab J., Vanni T.M., Ramakrishnan R., Ginsberg H.N. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J. Clin. Invest. 91:1993;1743-1752.
32. Jonas A. Synthetic substrates of lecithin:cholesterol acyltransferase. J. Lipid Res. 27:1986;689-698.
33. Clay M.A., Pyle D.H., Rye K.A., Barter P.J. Formation of spherical, reconstituted high density lipoproteins containing both apolipoproteins A-I and A-II is mediated by lecithin:cholesterol acyltransferase. J. Biol. Chem. 275:2000;9019-9025.
34. Ikewaki K., Zech L.A., Kindt M., Brewer H.B. Jr., Rader D.J. Apolipoprotein A-II production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-I:A-II in normolipidemic humans. Arterioscler. Thromb. Vasc. Biol. 15:1995;306-312.
35. Funke H., von Eckardstein A., Pritchard P.H., Hornby A.E., Wiebusch H., Motti C., et al. Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease. J. Clin. Invest. 91:1993;677-683.
36. Koizumi J., Inazu A., Yagi K., Koizumi I., Uno Y., Kajinami K., et al. Serum lipoprotein lipid concentration and composition in homozygous and heterozygous patients with cholesteryl ester transfer protein deficiency. Atherosclerosis. 90:1991;189-196.
37. Reymer P.W., Gagne E., Groenemeyer B.E., Zhang H., Forsyth I., Jansen H., et al. A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nat. Genet. 10:1995;28-34.
38. Breckenridge W.C., Little J.A., Alaupovic P., Wang C.S., Kuksis A., Kakis G., et al. Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atherosclerosis. 45:1982;161-179.
39. Glomset J.A., Norum K.R., Gjone E. Familial lecithin:cholesterol acyltransferase deficiency. Stanbury J.B., Wyngaarden J.B., Fredrickson D.S., Goldstein J.L., Brown M.S. Metabolic basis for inherited disease. 5th ed. 1983;643-654 McGraw-Hill Book Company, New York.
40. Mitchell C.D., King W.C., Applegate K.R., Forte T., Glomset J.A., Norum K.R., et al. Characterization of apolipoprotein E-rich density lipoproteins in familial lecithin:cholesterol acyltransferase deficiency. J. Lipid Res. 21:1980;625-640.
41. Yamashita S., Sprecher D.L., Sakai N., Matsuzawa Y., Tarui S., et al. Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with deficiency of cholesteryl ester transfer protein. J. Clin. Invest. 86:1990;688-695.
42. Ikewaki K., Rader D.J., Sakamoto T., Nishiwaki M., Wakimoto N., et al. Delayed catabolism of high density lipoprotein apolipoprotein A-I and A-II in human cholesteryl ester transfer protein deficiency. J. Clin. Invest. 92:1993;1650-1658.
43. Hegele R.A., Little J.A., Vezina C., Maguire G.F., Tu L., Wolever T.S., et al. Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics. Arterioscler. Thromb. Vasc. Biol. 13:1993;720-728.
44. Hoeg J.M., Santamarina-Fojo S., Berard A.M., et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc. Natl. Acad. Sci. USA. 93:1996;11448-11453.
45. Berard A.M., Remaley A.T., Vaisman B.L., et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat. Med. 3:1997;744-749.
46. Barter P.J., Rye K.A. Cholesteryl ester transfer protein, high density lipoprotein and arterial disease. Curr. Opin. Lipidol. 12:2001;377-382.
47. Sugano M., Makino N., Sawada S., Otsuka S., Watanabe M., Okamoto H., et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem. 273:1998;5033-5036.
48. Rittershaus C.W., Miller D.P., Thomas L.J., Picard M.D., Honan C.M., Emmett C.D., et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20:2000;2106-2112.
49. Okamoto H., Yonemori F., Wakitani K., Minowa T., Maeda K., Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 406:2000;203-207.
50. Marotti K.R., Castle C.K., Boyle T.P., Lin A.H., Murray R.W., Melchior G.W. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 364:1993;73-75.
51. Plump A.S., Masucci-Magoulas L., Bruce C., Bisgaier C.L., Breslow J.L., Tall A.R. Increased atherosclerosis in apoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler. Thromb. Vasc. Biol. 19:1999;1105-1110.
52. Foger B., Chase M., Amar M.J., Vaisman B.L., Shamburek R.D., Paigen B., et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J. Biol. Chem. 274:1999;36912-36920.
53. Hayek T., Masucci-Magoulas L., Jiang X., Walsh A., Rubin E., Breslow J.L., et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J. Clin. Invest. 96:1995;2071-2074.
54. Moriyama Y., Okamura T., Inazu A., Doi M., Iso H., Mouri Y., et al. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev. Med. 27:1998;659-667.
55. Hirano K., Yamashita S., Kuga Y., Sakai N., Nozaki S., Kihara S., et al. Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler. Thromb. Vasc. Biol. 15:1995;1849-1856.